Announcements Trials
Browse Landscape

Phase

Phase 2 14Phase 3 9Phase 1 2Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 21NIH 2OTHER_GOV 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Inflammatory Breast Neoplasms 1Breast Neoplasms 1

Interventions

Radiotherapy 13Cisplatin 8Cytarabine 7carfilzomib 5Specimen Handling 5Paclitaxel 5Dexamethasone 5Methotrexate 4Lapatinib 4Gemcitabine 4Fluorouracil 4Docetaxel 4Brachytherapy 4Biopsy 4venetoclax 3pomalidomide 3Temozolomide 3Radiotherapy, Conformal 3Leucovorin 3Irinotecan 3Etoposide 3Cyclophosphamide 3Carboplatin 3neratinib 2merphos 2Vincristine 2Radiation 2Polymerase Chain Reaction 2Oxaliplatin 2Immunohistochemistry 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × NETWORK × pegfilgrastim × Clear all
NCT00066443 2026-03-27

Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer

Canadian Cancer Trials Group

Phase 1/2 Completed
93 enrolled
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡